JP2012526846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526846A5 JP2012526846A5 JP2012511015A JP2012511015A JP2012526846A5 JP 2012526846 A5 JP2012526846 A5 JP 2012526846A5 JP 2012511015 A JP2012511015 A JP 2012511015A JP 2012511015 A JP2012511015 A JP 2012511015A JP 2012526846 A5 JP2012526846 A5 JP 2012526846A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- antibody
- human
- composition
- regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17792409P | 2009-05-13 | 2009-05-13 | |
| US61/177,924 | 2009-05-13 | ||
| PCT/US2010/034741 WO2010132683A1 (en) | 2009-05-13 | 2010-05-13 | Methods and compositions for treating lupus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250861A Division JP2015052021A (ja) | 2009-05-13 | 2014-12-11 | ループス治療のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526846A JP2012526846A (ja) | 2012-11-01 |
| JP2012526846A5 true JP2012526846A5 (enExample) | 2013-06-27 |
| JP5834004B2 JP5834004B2 (ja) | 2015-12-16 |
Family
ID=43085330
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511015A Active JP5834004B2 (ja) | 2009-05-13 | 2010-05-13 | ループス治療のための方法および組成物 |
| JP2014250861A Withdrawn JP2015052021A (ja) | 2009-05-13 | 2014-12-11 | ループス治療のための方法および組成物 |
| JP2016197833A Pending JP2017008106A (ja) | 2009-05-13 | 2016-10-06 | ループス治療のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250861A Withdrawn JP2015052021A (ja) | 2009-05-13 | 2014-12-11 | ループス治療のための方法および組成物 |
| JP2016197833A Pending JP2017008106A (ja) | 2009-05-13 | 2016-10-06 | ループス治療のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9617343B2 (enExample) |
| EP (2) | EP2429583A4 (enExample) |
| JP (3) | JP5834004B2 (enExample) |
| KR (1) | KR101800467B1 (enExample) |
| CN (2) | CN110179989B (enExample) |
| AU (2) | AU2010248935B2 (enExample) |
| BR (1) | BRPI1013927A2 (enExample) |
| CA (1) | CA2761885A1 (enExample) |
| IL (1) | IL216146A0 (enExample) |
| MX (1) | MX342907B (enExample) |
| RU (1) | RU2607022C2 (enExample) |
| WO (1) | WO2010132683A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY160126A (en) | 2009-05-13 | 2017-02-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| US20150073043A1 (en) * | 2012-01-19 | 2015-03-12 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| JP6400604B2 (ja) * | 2013-02-08 | 2018-10-03 | アレゲーニー・シンガー リサーチ インスティチュート | プレループス診断用バイオマーカーとしての細胞結合性補体活性産物 |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105051544B (zh) | 2013-03-20 | 2018-11-23 | 豪夫迈·罗氏有限公司 | 小鼠血清中大鼠抗体的特异性检测 |
| PT3105317T (pt) * | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| KR102632082B1 (ko) * | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| CN115058395B (zh) | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| WO2004042032A2 (en) * | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| US20060228351A1 (en) | 2003-03-31 | 2006-10-12 | Junichi Masuyama | Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor |
| CN1898267B (zh) | 2003-11-01 | 2012-05-23 | 默克专利股份有限公司 | 修饰的抗cd52抗体 |
| CA2562771C (en) | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
| CN101443040A (zh) * | 2006-03-16 | 2009-05-27 | 基因技术股份有限公司 | 用cd4抗体治疗狼疮的方法 |
| JP2009533350A (ja) | 2006-04-07 | 2009-09-17 | キメロス， インコーポレイテッド | Ｂ細胞悪性疾患を処置するための組成物および方法 |
| JP5541915B2 (ja) * | 2006-04-12 | 2014-07-09 | ジェンザイム・コーポレーション | 自己免疫疾患を治療する方法 |
| GB0608054D0 (en) | 2006-04-24 | 2006-05-31 | Isis Innovation | Production and use of regulatory t cells |
| CA2653848A1 (en) * | 2006-05-31 | 2007-12-06 | Genzyme Corporation | Methods of using anti-thymocyte globulin and related agents |
| AU2007275654A1 (en) | 2006-07-19 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | WSX-1/p28 as a target for anti-inflammatory responses |
| US8148067B2 (en) | 2006-11-09 | 2012-04-03 | Xdx, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| MY160126A (en) | 2009-05-13 | 2017-02-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
-
2010
- 2010-05-13 EP EP10775545.6A patent/EP2429583A4/en not_active Withdrawn
- 2010-05-13 EP EP17206028.7A patent/EP3345620B1/en active Active
- 2010-05-13 RU RU2011150495A patent/RU2607022C2/ru active
- 2010-05-13 CN CN201910644240.8A patent/CN110179989B/zh active Active
- 2010-05-13 WO PCT/US2010/034741 patent/WO2010132683A1/en not_active Ceased
- 2010-05-13 CA CA2761885A patent/CA2761885A1/en not_active Withdrawn
- 2010-05-13 KR KR1020117029688A patent/KR101800467B1/ko active Active
- 2010-05-13 US US13/320,001 patent/US9617343B2/en active Active
- 2010-05-13 AU AU2010248935A patent/AU2010248935B2/en active Active
- 2010-05-13 JP JP2012511015A patent/JP5834004B2/ja active Active
- 2010-05-13 CN CN2010800209534A patent/CN102438654A/zh active Pending
- 2010-05-13 MX MX2011012048A patent/MX342907B/es active IP Right Grant
- 2010-05-13 BR BRPI1013927A patent/BRPI1013927A2/pt not_active Application Discontinuation
-
2011
- 2011-11-03 IL IL216146A patent/IL216146A0/en active IP Right Grant
-
2014
- 2014-12-11 JP JP2014250861A patent/JP2015052021A/ja not_active Withdrawn
-
2016
- 2016-10-06 JP JP2016197833A patent/JP2017008106A/ja active Pending
-
2017
- 2017-03-01 US US15/446,162 patent/US20170369583A1/en not_active Abandoned
- 2017-03-15 AU AU2017201771A patent/AU2017201771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526846A5 (enExample) | ||
| RU2011150495A (ru) | Способы и композиции для лечения волчанки | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2006501240A5 (enExample) | ||
| JP2016074740A5 (enExample) | ||
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| WO2006008639A8 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| JP2010530902A (ja) | 流涎症治療のためのグリコピロレートを含む経皮送達システム | |
| JP2019521156A5 (enExample) | ||
| JP4272885B2 (ja) | コカイン依存症治療用薬剤 | |
| JP6770091B2 (ja) | ニコチン性アセチルコリン受容体アゴニストによる副鼻腔粘膜疾患を処置するための組成物及び方法 | |
| US6288026B1 (en) | Process and composition for treating diseases with an oil-in-water emulsion | |
| JP2024541122A (ja) | 疾患を治療するための免疫調節性物質を含む医薬組成物およびキット | |
| Ramakrishnan et al. | Treatment-related fluctuations in guillain Barre syndrome and the conundrum of additional cycles of plasmapheresis | |
| CA2364606C (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Jerabek | Pulsed magnetotherapy in Czechoslovakia-a review | |
| Kraft | Successful treatment of heavy smoker in one hour using split screen imagery, aversion, and suggestions to eliminate cravings | |
| Piedras et al. | Clinical care and evolution of paraplegic monkeys (Macaca mulatta) over fourteen months post-lesion | |
| Aandahl et al. | Preliminary experience with plasma exchange in patients with ulcerative colitis | |
| Kavanaugh et al. | Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status: Abstract Number: 1819 | |
| Dreschnack et al. | Case Report: Amyotrophic Lateral Sclerosis Treatment with Extracellular Vesicles derived from Mesenchymal Stromal Cells. Medical Research Archives,[online] 13 (9) | |
| JP2019511515A5 (enExample) | ||
| Feagan et al. | P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease |